Targeting breast cancer stem cells.
There is increasing evidence that many cancers, including breast cancer, contain populations of cells that display stem-cell properties. These breast cancer stem cells, by virtue of their relative resistance to radiation and cytotoxic chemotherapy, may contribute to treatment resistance and relapse. The elucidation of pathways that regulate these cells has led to the identification of potential therapeutic targets. A number of agents capable of targeting breast cancer stem cells in preclinical models are currently entering clinical trials. Assessment of the efficacy of the agents will require development of innovative clinical trial designs with appropriate biologic and clinical end points. The effective targeting of breast cancer stem cells has the potential to significantly improve outcome for women with both early-stage and advanced breast cancer.
Liu
Suling
S
Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Wicha
Max S
MS
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D011836:Radiation Tolerance; D015398:Signal Transduction
D000970:Antineoplastic Agents; D015415:Biomarkers